Changes in Hong Kong stocks | Goli Pharmaceutical-B (01672) rose more than 10% in the afternoon and reduced the prescription preparation ASC36_35FDC pre-clinical data released

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) rose more than 10% in the afternoon. As of press release, it rose 10.67% to HK$9.02, with a turnover of HK$10.3615 million.

According to the news, Goli Pharmaceuticals announced that key preclinical data on its reduced-dose formulation ASC36_35FDC was presented in the form of a brief oral discussion at the 62nd European Association for the Study of Diabetes (EASD) annual meeting. In a rat model of diet-induced obesity (DIO), the weight loss effect of this compound was relatively increased by 98% and 47% compared to eloralintide/tirpotide and MET-233i/tirzepatide, respectively, and showed extremely long-lasting characteristics supporting monthly or even quarterly administration.

According to public information, ASC36_35FDC is a compound therapy developed independently using Goli's proprietary structure-based AI-assisted drug discovery and ultra-long-lasting drug development platform technology. It is positioned as “promising to be the best treatment candidate in its class.” Recently, the company announced that it has initiated a US Phase I study on ASC36 oral tablets for the treatment of obesity after receiving FDA approval from IND.